To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

Johnson & Johnson (J&J)

Status

Completed

Conditions

Atopic Dermatitis

Treatments

Device: F# 10495-053

Device: F# 11054-010

Study type

Interventional

Funder types

Industry

Identifiers

NCT00886587

EMOECZ0002

Details and patient eligibility

About

The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in comparison to that of a similar marketed product. This study was conducted to assess the safety of the investigational new study product and how well it works to treat AD in children, by making AD visually better, and reducing the amount of itch.

Full description

This was a multi-center, double-blind, randomized, active-controlled trial in children 2 to 12 years of age with mild to moderate AD. A sufficient number of subjects were screened to ensure that approximately 80 subjects were randomized, to yield 70 completed subjects. Subjects were randomized to one of the two treatment groups: the J&J Device or Atopiclair®. All subjects were to return to the clinical site for clinical assessments at baseline (Day 1) and at Days 3, 8, 15, 22, 29 and 43 after initial investigational product application. The investigational products were used topically during the duration of the study.

Enrollment

82 patients

Sex

All

Ages

2 to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Post-menarchal female subjects must have a negative urine pregnancy test
Willing to provide written informed consent/assent
Diagnosed as having mild to moderate Atopic Dermatitis (AD)
Willing to stop all moisturizers and/or other skin barrier cream or emulsion treatments for the AD condition during the test period and replace with the investigational product assigned in this trial
Willing to replace their body wash and/or soaps with the one provided in this trial

Exclusion criteria

Severe AD as determined by the Rajka-Langeland Severity Index
AD requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids. If the subject requires any of these medications as rescue therapy during the study, the subject will be discontinued from the trial
History of allergy or hypersensitivity to the ingredients of the test devices, nuts or nut oil
Cutaneous or systemic viral (including HIV or AIDS), mycotic or bacterial disease requiring a topical or systemic therapy
Diabetes mellitus that cannot be controlled by diet alone (i.e., requires systemic medications for control)